Increased Expression of Interleukin-1 Receptor Characterizes Anti-estrogen-Resistant ALDH⁺ Breast Cancer Stem Cells.

ABSTRACT: Estrogen-receptor-positive breast tumors are treated with anti-estrogen (AE) therapies but frequently develop resistance. Cancer stem cells (CSCs) with high aldehyde dehydrogenase activity (ALDH⁺ cells) are enriched following AE treatment. Here, we show that the interleukin-1β (IL-1β) signaling pathway is activated in ALDH⁺ cells, and data from single cells reveals that AE treatment selects for IL-1 receptor (IL1R1)-expressing ALDH⁺ cells. Importantly, CSC activity is reduced by an IL1R1 inhibitor in AE-resistant models. Moreover, IL1R1 expression is increased in the tumors of patients treated with AE therapy and predicts treatment failure. Single-cell gene expression analysis revealed that at least two subpopulations exist within the ALDH⁺ popul

SUBMITTER: Sarmiento-Castro A 

PROVIDER: S-EPMC7419713 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature